Day One Biopharmaceuticals (DAWN) Stock Forecast & Price Target

Compare

398 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DAWN Analyst Ratings

Strong Buy

8 Buy

1 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Day

One Biopharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DAWN Stock 12 Month Forecast

Average Price Target

$23.75

▲(157.03% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Day One Biopharmaceuticals in the last 3 months. The average price target is $23.75 with a high forecast of $34.00 and a low forecast of $16.00. The average price target represents a 157.03% change from the last price of $9.24.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","20":"$20","35":"$35","12.5":"$12.5","27.5":"$27.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$34.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,12.5,20,27.5,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.44,9.483076923076924,11.526153846153846,13.56923076923077,15.612307692307692,17.655384615384616,19.69846153846154,21.74153846153846,23.784615384615385,25.82769230769231,27.87076923076923,29.913846153846155,31.95692307692308,{"y":34,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.44,8.694615384615386,9.94923076923077,11.203846153846154,12.458461538461538,13.713076923076922,14.967692307692307,16.22230769230769,17.476923076923075,18.73153846153846,19.986153846153844,21.240769230769228,22.495384615384616,{"y":23.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.44,8.098461538461539,8.756923076923076,9.415384615384616,10.073846153846153,10.732307692307693,11.39076923076923,12.049230769230768,12.707692307692307,13.366153846153846,14.024615384615384,14.683076923076921,15.341538461538459,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.65,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.67,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.37,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.06,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.61,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.01,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.61,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.88,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.44,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$34.00

Average Price Target$23.75

Lowest Price Target$16.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ami Fadia

Needham

$16

Buy

73.16%

Upside

Reiterated

11/24/25

Promising Clinical Results and Growth Potential Reinforce Buy Rating for Day One Biopharmaceuticals' OjemdaWe believe these data should support continued growth of Ojemda's use in 2L pLGG. We reiterate our Buy rating and look for momentum in DAWN with continued execution on Ojemda, and data updates on recently acquired Emi-Le in ACC and DAY-301, the PTK7 ADC currently in dose optimization.

Andres Y. Maldonado

H.C. Wainwright

$25

Buy

170.56%

Upside

Reiterated

11/24/25

Buy Rating Affirmed for Day One Biopharmaceuticals: Promising FIREFLY-1 Trial Results and Ojemda's Market PotentialValuation and Risks. Our price target of $25 is based on an equally weighted composite of: (a) $22.75/share, as a 25x multiple of taxed and diluted FY34 GAAP EPS of $2.52 discounted back to and (b) an NPV of $26.7/share (discount rate 12%, terminal growth rate of 2.0%). Risks to our investment thesis and target price include: (1) regulatory risk; (2) commercial risks; (3) clinical development risks; (4) manufacturing risks; (5) financial risks; (6) liability risks; and (7) intellectual property risk.

Soumit Roy

JonesTrading

$20

Buy

116.45%

Upside

Reiterated

11/24/25

Buy Rating Affirmed for Day One Biopharmaceuticals Based on Promising Long-Term Data from FIREFLY-1 Trial

Matthew Biegler

Oppenheimer

―

Hold

―

Reiterated

11/13/25

Analysts Conflicted on These Healthcare Names: Bioxcel Therapeutics (NASDAQ: BTAI) and Day One Biopharmaceuticals (NASDAQ: DAWN)

Alec Stranahan

Bank of America Securities

$17

Buy

83.98%

Upside

Reiterated

11/13/25

Strategic Acquisition of Mersana Therapeutics Boosts Day One Biopharmaceuticals' Market Potential: Buy Rating Affirmed

Anupam Rama

J.P. Morgan

$26→$27

Buy

192.21%

Upside

Reiterated

11/07/25

Day One Biopharmaceuticals price target raised to $27 from $26 at JPMorganDay One Biopharmaceuticals price target raised to $27 from $26 at JPMorgan

Kelsey Goodwin

Piper Sandler

$25→$26

Buy

181.39%

Upside

Reiterated

11/05/25

Day One Biopharmaceuticals price target raised to $26 from $25 at Piper SandlerDay One Biopharmaceuticals price target raised to $26 from $25 at Piper Sandler

Tara Bancroft

TD Cowen

$34

Buy

267.97%

Upside

Reiterated

11/04/25

Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (NASDAQ: DAWN) and Sandoz Group Ltd (Other OTC: SDZXF)

Robert Driscoll

Wedbush

$25

Buy

170.56%

Upside

Reiterated

11/04/25

Andrea Tan

Goldman Sachs

$18

Buy

94.81%

Upside

Reiterated

07/15/25

Day One Biopharmaceuticals (DAWN) Gets a Buy from Goldman Sachs

Joseph Catanzaro

Mizuho Securities

$40

Buy

332.90%

Upside

Reiterated

02/26/25

Piper Sandler Sticks to Its Buy Rating for Day One Biopharmaceuticals (DAWN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ami Fadia

Needham

$16

Buy

73.16%

Upside

Reiterated

11/24/25

Andres Y. Maldonado

H.C. Wainwright

$25

Buy

170.56%

Upside

Reiterated

11/24/25

Soumit Roy

JonesTrading

$20

Buy

116.45%

Upside

Reiterated

11/24/25

Buy Rating Affirmed for Day One Biopharmaceuticals Based on Promising Long-Term Data from FIREFLY-1 Trial

Matthew Biegler

Oppenheimer

―

Hold

―

Reiterated

11/13/25

Analysts Conflicted on These Healthcare Names: Bioxcel Therapeutics (NASDAQ: BTAI) and Day One Biopharmaceuticals (NASDAQ: DAWN)

Alec Stranahan

Bank of America Securities

$17

Buy

83.98%

Upside

Reiterated

11/13/25

Strategic Acquisition of Mersana Therapeutics Boosts Day One Biopharmaceuticals' Market Potential: Buy Rating Affirmed

Anupam Rama

J.P. Morgan

$26→$27

Buy

192.21%

Upside

Reiterated

11/07/25

Day One Biopharmaceuticals price target raised to $27 from $26 at JPMorganDay One Biopharmaceuticals price target raised to $27 from $26 at JPMorgan

Kelsey Goodwin

Piper Sandler

$25→$26

Buy

181.39%

Upside

Reiterated

11/05/25

Day One Biopharmaceuticals price target raised to $26 from $25 at Piper SandlerDay One Biopharmaceuticals price target raised to $26 from $25 at Piper Sandler

Tara Bancroft

TD Cowen

$34

Buy

267.97%

Upside

Reiterated

11/04/25

Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (NASDAQ: DAWN) and Sandoz Group Ltd (Other OTC: SDZXF)

Robert Driscoll

Wedbush

$25

Buy

170.56%

Upside

Reiterated

11/04/25

Andrea Tan

Goldman Sachs

$18

Buy

94.81%

Upside

Reiterated

07/15/25

Day One Biopharmaceuticals (DAWN) Gets a Buy from Goldman Sachs

Joseph Catanzaro

Mizuho Securities

$40

Buy

332.90%

Upside

Reiterated

02/26/25

Piper Sandler Sticks to Its Buy Rating for Day One Biopharmaceuticals (DAWN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Day One Biopharmaceuticals

1 Month

xxx

Success Rate

10/17 ratings generated profit

Average Return

+3.88%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 58.82% of your transactions generating a profit, with an average return of +3.88% per trade.

3 Months

xxx

Success Rate

7/17 ratings generated profit

Average Return

-2.22%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 41.18% of your transactions generating a profit, with an average return of -2.22% per trade.

1 Year

Alec StranahanBank of America Securities

Success Rate

10/17 ratings generated profit

Average Return

-0.45%

reiterated a buy rating last month

Copying Alec Stranahan's trades and holding each position for 1 Year would result in 58.82% of your transactions generating a profit, with an average return of -0.45% per trade.

2 Years

xxx

Success Rate

9/17 ratings generated profit

Average Return

+0.49%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 52.94% of your transactions generating a profit, with an average return of +0.49% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DAWN Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DAWN has received 18 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. DAWN average Analyst price target in the past 3 months is 23.75.

Each month's total comprises the sum of three months' worth of ratings.

DAWN Financial Forecast

DAWN Earnings Forecast

Next quarter’s earnings estimate for DAWN is -$0.19 with a range of -$0.23 to -$0.16. The previous quarter’s EPS was -$0.19. DAWN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year DAWN has Performed in-line its overall industry.

DAWN Sales Forecast

Next quarter’s sales forecast for DAWN is $43.81M with a range of $37.54M to $46.10M. The previous quarter’s sales results were $39.80M. DAWN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year DAWN has Performed in-line its overall industry.

DAWN Stock Forecast FAQ

What is DAWN’s average 12-month price target, according to analysts?

Based on analyst ratings, Day One Biopharmaceuticals, Inc.’s 12-month average price target is 23.75.

What is DAWN’s upside potential, based on the analysts’ average price target?

Day One Biopharmaceuticals, Inc. has 157.03% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DAWN a Buy, Sell or Hold?

Day One Biopharmaceuticals, Inc. has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

What is Day One Biopharmaceuticals, Inc.’s price target?

The average price target for Day One Biopharmaceuticals, Inc. is 23.75. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $34.00 ,the lowest forecast is $16.00. The average price target represents 157.03% Increase from the current price of $9.24.

What do analysts say about Day One Biopharmaceuticals, Inc.?

Day One Biopharmaceuticals, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of DAWN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Day One Biopharmaceuticals (DAWN) Stock Forecast & Price Target

DAWN Analyst Ratings

DAWN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Day One Biopharmaceuticals

DAWN Analyst Recommendation Trends

DAWN Financial Forecast

DAWN Earnings Forecast

DAWN Sales Forecast

DAWN Stock Forecast FAQ

Detailed List of Analyst Forecasts